About the Company
We do not have any company description for Black Diamond Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors
As the major U.S. stock indices hover near record highs following two consecutive weeks of gains, investors are closely monitoring economic indicators and corporate earnings for signs of market ...
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics ...
--Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the formation of Launchpad Therapeutics ...
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate ...
Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership oppo ...
Black Diamond Therapeutics Reports Third Quarter 2024 ... - Nasdaq
--Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial ...
Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock ...
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported a net loss of $18.2 million during the first quarter of 2024, down from $20.9 million for the same period in 2023.
Black Diamond Therapeutics Announces Changes to Board of Directors
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
Black Diamond Therapeutics Reports Promising Q3 2024 Results
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company specializing in developing MasterKey therapies to target families of oncogenic mutations in cancer patients, aiming to ...
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results ...
CAMBRIDGE, Mass. and NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
Black Diamond Therapeutics Inc. - Barron's
Complete Black Diamond Therapeutics Inc. stock information by Barron's. View real-time BDTX stock price and news, along with industry-best analysis.
Black Diamond Therapeutics Announces Changes to Board of Directors
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (BDTX), a precision oncology medicine company pioneering the discovery and development of ...
Similar Companies
Loading the latest forecasts...